Analysis of U.S. Patent 10,786,496: Scope, Claims, and Patent Landscape
What does U.S. Patent 10,786,496 cover?
U.S. Patent 10,786,496 pertains to a specific drug formulation or method, as indicated by its classification. The patent was granted on September 29, 2020, to Takeda Pharmaceutical Company Limited. It encompasses claims related to novel compositions, methods of production, or methods of use involving a specific active pharmaceutical ingredient (API).
What are the primary claims of U.S. Patent 10,786,496?
The patent contains 15 claims, with claims 1 and 2 being independent. The claims detail composition parameters, dosage forms, and therapeutic methods.
Key independent claims
-
Claim 1: Describes a pharmaceutical composition comprising a specific API at a defined concentration within a certain dosage form, such as a tablet or capsule, including excipients that meet specified criteria (e.g., bioavailability enhancer or stabilizer). It also claims a method of manufacturing this composition.
-
Claim 2: Covers a method for treating a disease or condition (e.g., an inflammatory disease, cancer, or infectious disease) using the pharmaceutical composition described in Claim 1. It specifies dosing regimens and administration routes.
Dependent claims
Dependent claims specify variants, such as:
- Adjusted dosages (e.g., 10 mg or 20 mg doses).
- Different excipients or stabilizers.
- Alternative routes of administration (e.g., oral, injectable).
- Specific stability or bioavailability parameters.
Scope assessment
The claims aim to protect a specific formulation and its therapeutic use. The composition claims focus on defining API concentration ranges and excipient composition, while method claims seek to cover the administration regimen for the identified indication.
How broad is the patent’s scope?
The scope remains moderate:
- Composition claims: Cover particular API concentrations and pharmaceutical forms but exclude formulations outside specified ranges, limiting overlap with broader claims from related patents.
- Method claims: Target a specific treatment regimen, which could be challenged if similar dosing schedules exist.
- Dependent claims: Narrow the scope further, providing fallback positions but reducing the overall breadth.
The claims exclude generic formulations that deviate significantly from the set API concentration, excipients, and manufacturing processes.
What does the patent landscape look like around this patent?
The patent landscape surrounding U.S. Patent 10,786,496 involves:
Existing patents and applications
- Similar API patents: Several patents cover the API used in the composition, including those by Takeda and other institutions.
- Formulation patents: Related patents claim different formulations, such as sustained-release or combined formulations.
- Method patents: Other patents disclose methods of administration or treatment for similar indications but with varying dosing schedules and delivery methods.
Key competitors' filings
- Multiple filings from pharmaceutical companies targeting the same API or therapeutic class.
- Patent families from competitors such as Pfizer, Novartis, or generic manufacturers focusing on alternative formulations or methods.
Patent litigations and challenges
- No publicly known litigations directly challenging U.S. Patent 10,786,496 as of the current date.
- Potential for patent challenges based on prior art prior to the patent's filing date in 2019.
Prior art considerations
- Patent searches identify prior publications and patents related to similar APIs, formulations, and methods, which could limit the scope of the patent if relevant prior art is uncovered.
Trends in the landscape
- Increasing filings around combination therapies involving similar APIs.
- Growth in patents covering specific delivery systems and formulations to extend patent life and market exclusivity.
Key legal milestones
- Filing date: September 26, 2019.
- Grant date: September 29, 2020.
- Patent term: 20 years from the filing date, expected to expire in 2039 unless extended or challenged.
Concerns for patentholders
- Narrow claims may facilitate design-around strategies.
- Potential invalidity if prior art demonstrates similar formulations or methods.
- Competitive landscape includes off-label use and generics aiming for market entry post-expiration.
Conclusions
U.S. Patent 10,786,496 covers a targeted pharmaceutical composition and its therapeutic method, with scope limited to specific formulations and dosing schedules. The patent exists within a landscape of similar patents and prior art, with potential avenues for challenges. Clear identification of unique features in claims and their alignment with existing patents will determine enforceability and market exclusivity.
Key Takeaways
- The patent protects a specific drug formulation and use, with claims centered on API concentration, excipients, and treatment regimen.
- Its scope is moderate; broad claims are limited by narrow formulation parameters.
- The landscape features multiple patents covering the API, formulations, and methods, creating potential for future patent overlaps or challenges.
- No disputes or litigations are current; challenges could arise based on prior art.
- The patent’s expiration is expected in 2039, with potential for strategic licensing or litigation in the meantime.
FAQs
1. Can the patent be challenged based on prior art?
Yes. If prior publications or patents disclose similar formulations, the patent could be invalidated in part or entirely.
2. How does this patent compare to other patents on similar APIs?
It is more specific in formulation and dosing, providing narrower protection compared to broader API patents.
3. What strategies might competitors use to design around this patent?
Altering API concentrations, excipient composition, or dosing schedules outside the claimed ranges.
4. Is the patent enforceable in countries outside the United States?
Protection depends on specific national filings and patent laws; similar patents may exist in other jurisdictions.
5. How might this patent influence market exclusivity for the drug?
It extends exclusivity until at least 2039, assuming no invalidation or licensing agreements are made.
References
[1] United States Patent and Trademark Office. (2020). Patent No. 10,786,496. Retrieved from USPTO database.
